<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335307">
  <stage>Registered</stage>
  <submitdate>31/03/2010</submitdate>
  <approvaldate>7/04/2010</approvaldate>
  <actrnumber>ACTRN12610000280000</actrnumber>
  <trial_identification>
    <studytitle>The NACIAM Study  Assessing the benefit of N-Acetylcysteine (NAC) in acute heart attacks.</studytitle>
    <scientifictitle>The early use of N-Acetyl Cysteine In Acute Myocardial Infarction to assess the impact of early NAC therapy in reducing myocardial infarct size as determined by Cardiac Magnetic Resonance Imaging (CMRI).</scientifictitle>
    <utrn>U1111-1114-5373</utrn>
    <trialacronym>NACIAM</trialacronym>
    <secondaryid>none</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Acute ST Elevation Myocardial Infarction requiring urgent revascularisation (angioplsty or stent).  The ST segment refers to that of QRST complex as represented on a 12 lead ECG (Electrocardiograph).</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Intravenous (I.V.) N-Acetyl Cysteine (NAC) 15g or saline placebo in 500 mls 5% Dextrose delivered at 20 mg/min for 1st hour then 10 mg/min for next 47 hours.  This is a one-off treatment.</interventions>
    <comparator>Corresponding saline placebo is administered as soon as the decision for acute intervention has been made.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Myocardial infarct size as determined by Cardiac Magnetic Resonance Imaging (MRI).</outcome>
      <timepoint>First post-infarct week.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Angiography patency and infarct size measured at time of angiography.</outcome>
      <timepoint>Measured at angiography during index event.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Acute ST segment elevation myocardial infarction (STEMI) with primary percutaneous coronary intervention.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Previous myocardial infarction. 
Permanent pacemaker or implantable defibrillator (cardiac MRI contra-indicated).
Decision to administer open-label NAC for renoprotection</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Patients presenting to participating hospitals with an acute STEMI, will be allocated blinded, numbered and sealed treatment boxes by number sequential randomisation.</concealment>
    <sequence>Treatment arms will be pre-determined by a computer-generated algorithm with randomisation blocks of 10.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3 / Phase 4</phase>
    <anticipatedstartdate>28/02/2010</anticipatedstartdate>
    <actualstartdate>4/03/2010</actualstartdate>
    <anticipatedenddate>1/01/2012</anticipatedenddate>
    <actualenddate>9/03/2013</actualenddate>
    <samplesize>80</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>The Queen Elizabeth Hospital Cardiology Unit</primarysponsorname>
    <primarysponsoraddress>28 Woodville Road
Woodville 
South Australia 5011</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>The National Heart Foundation of Australia</fundingname>
      <fundingaddress>155-159 Hutt Street 
Adelaide
South Australia 5000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>N-Acetylcysteine (NAC) is an anti-oxidant which also potentiates the action of nitroglycerine. When used with nitrates in the context of acute myocardial infarction, it may reduce infarct size by minimising reperfusion injury as well as potentiating nitroglycerine's vasodilating and anti-platelet effects.  The NACIAM trial is a randomised, double-blind, placebo-controlled study assessing the impact of early NAC therapy in reducing infarct size (as assessed by cardiac MRI) in patients with acute ST elevation myocardial infarction receiving intravenous nitrate therapy and undergoing primary percutaneous coronary intervention.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Central Northern Adelaide Health Service Ethics of Human Research Committee, The Queen Elizabeth Hospital (TQEH), The Lyell McEwin Hospital (LMH) and Modbury Hospital, (MH)</ethicname>
      <ethicaddress>The Queen Elizabeth Hospital
Adelaide</ethicaddress>
      <ethicapprovaldate>30/09/2008</ethicapprovaldate>
      <hrec>2008087</hrec>
      <ethicsubmitdate>30/05/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Professor John Beltrame</name>
      <address>The Queen Elizabeth Hospital
28 Woodville Road
Woodville 
South Australia 5011</address>
      <phone>+61 8 8222 6000</phone>
      <fax>+61 8 8222 7201</fax>
      <email>marilyn.black@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Professor John Beltrame  </name>
      <address>The Queen Elizabeth Hospital
28 Woodville Road
Woodville 
South Australia 5011</address>
      <phone>+61 8 8222 6000</phone>
      <fax>+61 8 8222 7201</fax>
      <email>marilyn.black@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>John Beltrame</name>
      <address>The Queen Elizabeth Hospital
28 Woodville Road
Woodville South
SA 5011</address>
      <phone>+61 8 8222 6000</phone>
      <fax />
      <email>john.beltrame@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>